Chemistry Scholarships
The Department typically admits 50-60 PhD and 130 - 140 MRes students each year. Funding for these students comes from a diverse range of sources, including the EPSRC, industry, scholarships and self-funded students. A selection of PhD Studentships currently available are detailed below.
Accordion - available studentships
- Chemistry International Continuation PhD Scholarship
- Department of Chemistry Departmental PhD Scholarships
- EPSRC CDT in Chemical Biology - Empowering UK BioTech Innovation
- PhD position available in Machine Learning and Automation of Polymer Nanogel Discovery for Mitochondria Delivery
- Novel carbonylation homologation strategies for peptide bond formation - Dr Phil Miller
- PhD opportunity with Ass. Prof. Jarvist Frost - Developing new theoretical techniques for the design of functional materials
- PhD position available in Synthetic Chemistry for Development of Mitochondria Targeting and Genome Engineering.
- PhD position available in High-Throughput Biological Screening Platforms for Mitochondrial Genome Engineering
- PhD Studentship in Chemical Biology - Enzymatic Synthesis of Peptide Therapeutics
- Exploiting the Nuclear Recoil (Szilárd–Chalmers) Effect for the Separation of Neutron Irradiated Isotopes from Advanced Target Matrices
This scholarship offers a full fee waiver for the last academic year of a PhD for recent Imperial graduates. The recipients of this scholarship will be expected to finish the PhD project within 3 years, with the first 2 years of fees being funded by the applicant. In case any extensions are needed beyond 3 years, these would have to be funded by the applicant. Only Imperial College graduates that have overseas fee status are eligible to apply. The Department encourages diversity and will accept a high merit degree classification from applicants. For more information please contact chemphd@imperial.ac.uk.
The Department of Chemistry has departmental scholarships available for PhD applicants starting in 2027/28.
This scheme is only eligible to applicants who have home fee status. The scholarship will cover the full fees and stipend (UKRI London rate - £22,780 for 2025-26) for the 3 years 6 months of the student’s PhD studies.
We encourage applications from all backgrounds to apply. The Departmental Scholarship Panel will consider academic excellence, research potential and extracurricular activities. The Panel will also take into account other aspects, such as overcoming adversity, outreach and community activities and widening participation.
Interested candidates should make contact and discuss a research project with a PhD supervisor based in the Chemistry Department. After discussions with the chosen supervisor, candidates must complete a Chemistry Department scholarship application form. The supervisor will then return the documentation to the department for consideration by the Scholarship Panel. The date for submission of this documentation is Tuesday 1st December 2026. There will be no panel interview.
We are committed to equality and valuing diversity. The Department of Chemistry is an Athena SWAN gold Award winner, a Stonewall Diversity Champion, a Two Ticks Employer, and is working in partnership with GIRES to promote respect for trans people. We particularly encourage applicants from underrepresented backgrounds to apply.
The mission of the ICB CDT is to train postgraduate researchers with the language, knowledge and skills to enable them to work at the interface between the physical and life sciences, producing researchers with expertise and understanding that spans both fields, and who are able to embrace Lab of the Future platforms – which is at the heart of our new remit. This skill set is in great demand from future employers and short supply and has the potential to revolutionise the state of the art with respect to manipulating, measuring and modelling molecular interactions in biological systems and will transform R&D pipelines.
This will transform our understanding of molecular mechanisms of disease, stimulate novel agrochemical design and underpin structured product breakthroughs, whilst also enabling fundamental discovery in the life and medical sciences.
Our programme, with EDI, student empowerment & cohort formation at its core, fuses blue skies & translational research with professional skills courses and workplace training. Students emerge with a knowledge of molecular technologies, sustainable product development, lean innovation & early-stage commercialisation. Our multi-disciplinary supervision model, with every student in the CDT having at least two supervisors, one from the physical sciences and one from the life sciences, comprises 1-year MRes + 3-year PhD, with for the first time an optional 1 year post doctoral fellowship, called Elevate, that will offer graduates unparalleled in-work experience.
PhD position available in Machine Learning and Automation of Polymer Nanogel Discovery for Mitochondria Delivery
Start date: Oct 2026
Applications will be reviewed on a rolling basis.
A PhD position is available as part of an ARIA-funded project, PIONEER. Further details about the broader PIONEER project are given in the next two paragraphs. This PhD position will work with Prof. Kim Jelfs, Dr. Becky Greenaway and Dr. Nazila Kamaly in the Department of Chemistry at Imperial College London. Your role will be to develop and apply machine learning to accelerate the optimisation of precision polymer nanogels for programmable mitochondria delivery. This will involve the further development of in-house machine learning-based optimisation algorithms to allow optimisation of the biophysiochemical properties of the polymer nanogels. Alongside this you will explore the utility of other machine learning architectures, such as the use of foundational models for data extraction, structure-property analysis and supervised machine learning models for property prediction. The role is likely to also include the use of experimental chemical automated platforms for the generation and testing of new nanogels together with a PIONEER post-doc. You will contribute to the incorporation of your active learning optimisation software with these experimental platforms.
PIONEER (Programmable In-Organelle Nucleic-acid Entry, Expression and Retention) is an ambitious UK research consortium from Imperial College London, the University of Bristol, and the University of Glasgow, funded through the UK’s Advanced Research and Innovation Agency’s (ARIA) Precision Mitochondria programme, with a single bold goal: to build, from end to end, the ability to engineer the genome of mitochondria, the energy-producing compartments inside our cells. Mitochondria carry their own small genome, and reliably installing new, synthetic genetic material inside them has long been one of the great unsolved problems in biology. PIONEER sets out to crack it: to deliver large pieces of synthetic mitochondrial DNA across the mitochondria's notoriously difficult double membrane, switch on new genes inside, and make those changes stable over time. Ultimately, PIONEER seeks to demonstrate successful mitochondrial genome engineering in vivo and thereby open a new frontier for fundamental biology and for future therapies against mitochondrial disease.
PIONEER is deliberately interdisciplinary, bringing together across the larger team expertise in nanomaterials and drug delivery; automation, AI and machine learning for chemistry; synthetic cell engineering; single-molecule biophysics; advanced spectroscopy; genome engineering; and single-cell genetics. You would be joining a large collaborative team of post-docs and PhD students and so it is a rare opportunity to work at the intersection of several cutting-edge fields on a problem that will not only bring exciting new fundamental insights but also, if solved, would be a significant scientific breakthrough.
The position is available to candidates holding, or about to hold, a Masters degree in Chemistry, or in a related field if the applicability of the experience can be demonstrated. A background in one of the following is desirable, but not essential, as full training in the required techniques will be provided: nanoparticle design, synthesis and engineering, computational chemistry, machine learning for chemistry or high-throughput techniques/chemical automation. Full funding is available for UK Home students only. This role is part of an Advanced Research + Invention Agency-funded project, subject to contract negotiations.
Interested applicants are encouraged to contact both Prof. Kim Jelfs (k.jelfs@imperial.ac.uk) and Dr. Becky Greenaway (r.greenaway@imperial.ac.uk and Dr. Nazila Kamaly (nazila.kamaly@imperial.ac.uk) by email, describing their interest in the field and any prior research experience along with a CV.
Funding Notes
Applicants should also clearly state how they are eligible for Home fee status (for example through UK citizenship or because they hold Settled Status, more information about fee status can be found here: View Website).
Novel carbonylation homologation strategies for peptide bond formation
Supervisors: Dr Philip Miller (Imperial College London) and Dr Christan Holtze (BASF)
Home Department: Departments of Chemistry at Imperial College London, Molecular Sciences Research Hub
White City Campus
Funding and Deadline: To be eligible for support, applicants must be “UK Residents” as defined by the EPSRC. The studentship is for 4 years starting as soon as possible and will provide full coverage of standard tuition fees and an annual tax-free stipend of approximately £21,240. Applicants should hold or expect to obtain a First-Class Honours or a high 2:1 degree at master's level (or equivalent) in any relevant chemical engineering or science subject. Funding is co-funded through Engineering and Physical Sciences Research Council (EPSRC) and BASF.
Project summary
Novel peptide therapeutics are experiencing burgeoning growth in the pharmaceutical sector. One of the chief challenges, however, in the peptide market is their high production costs. This is a direct result of the various protecting group strategies and reagents that mediate amino-carboxylic acid coupling. Challenges therefore remain in the efficient production of peptides, including low atom economy due to the protecting group strategies, excess use of reagents and vast amounts of solvents needed for purifications.
This project seeks to explore new strategies for peptide synthesis via amide formation using novel catalytic carbonylative coupling methods. Historically, carbonylation reactions have been conducted using high pressures of carbon monoxide and a transition metal catalyst at high temperatures, however, recent advances in catalytic directing group chemistry, C-H activations and photocatalysis have opened alternative routes to efficient amide bond formation. This project will focus on novel catalytic strategies that exploit new photocatalysts, have different mechanisms and can be conducted under milder reaction conditions. We will seek to exploit emerging chemical strategies for peptide bond formation and to leverage advances in flow chemistry for performing and scaling up these reactions.
We are seeking an ambitious and highly motivated candidate with experience of synthetic chemistry (organic or inorganic) who is willing to work with industry partners. You will investigate a range of catalytic and photocatalytic reaction processes primarily for the insertion of carbon monoxide for the preparation of small organic carbonyl molecules and peptides.
The Industry Case (IDLA) PhD student will join an interdisciplinary cohort of students working under the umbrella of the IConIC Prosperity Partnership. An internship of min. 3 months will be facilitated and sponsored by BASF- Chemetall for the utilization of specific infrastructure and technology transfer.
To apply, please complete an application form Application process | Study | Imperial College London. Informal enquiries about the post and the application process can be made to Genevieve Prescott (iconic-pp@imperial.ac.uk).
Deadline for applications is the 31st May 2026.
Eligibility for student funding: https://www.ukri.org/councils/esrc/career-and-skills-development/funding-for-postgraduate-training/eligibility-for-studentship-funding/
A PhD position funded on Jarvist Moore Frost's Royal Society University Research Fellowship is available for a January-October 2026 start date.
The two projects being actively recruited for are:
1) Designing antimicrobial peptides with machine learning and computational chemistry approaches
2) Machine learning surrogate quantum mechanical models (particularly Tight-binding and PPP)
Both these proects focus on developing new theoretical techniques, for the design of functional materials (peptide drugs and organic semiconductors, respectively). There will be considerable training in the use of computational chemistry and data-driven (machine learning) approaches. You will be part of a research team of Research Associates and PhD students. Both projects are tightly linked to making synthesis predictions. These predictions will then be tested in novel synthesis and measurements on the resulting compounds, during the time period of the PhD. Though the projects are mainly theoretical / computational, there is scope to get involved in the experiments.
The position is available to candidates holding, or about to hold, a Masters degree in Chemistry, Physics or Materials, or in a related field if the applicability of the experience can be demonstrated. A background in one of the following is desirable, but not essential, as full training in the required techniques will be provided: quantum chemistry / electronic structure theory, computer programming, experience of the specific research area of the projects. In the group we have a strong focus on modern research software engineering, with industry best practices.
Interested applicants are encouraged to contact Dr Jarvist Moore Frost (jarvist.frost@imperial.ac.uk) by email, describing their interest in the field and any prior research experience along with a curriculum vitae (CV).
Please see https://docs.google.com/document/d/1N-jxP1Zp_wY5iSttc1X7JVxsCnbFomiC4WtLTiMTWiA/edit?usp=sharing for more detail about the research team and proposed projects.
Funding notes
Full funding is available for UK Home students.
Applicants should clearly state how they are eligible for Home fee status, for example through UK citizenship or because they hold Settled Status. More information about fee status can be found here: https://www.imperial.ac.uk/study/fees-and-funding/tuition-fees/fee-status/).
About the Project
PIONEER (Programmable In-Organelle Nucleic-acid Entry, Expression and Retention) is an ambitious UK research consortium from Imperial College London, the University of Bristol, and the University of Glasgow, funded through the UK’s Advanced Research and Innovation Agency’s (ARIA) Precision Mitochondria programme, with a single bold goal: to build, from end to end, the ability to engineer the genome of mitochondria, the energy-producing compartments inside our cells. Mitochondria carry their own small genome, and reliably installing new, synthetic genetic material inside them has long been one of the great unsolved problems in biology. PIONEER sets out to crack it: to deliver large pieces of synthetic mitochondrial DNA across the mitochondria's notoriously difficult double membrane, switch on new genes inside, and make those changes stable over time. Ultimately, PIONEER seeks to demonstrate successful mitochondrial genome engineering in vivo and thereby open a new frontier for fundamental biology and for future therapies against mitochondrial disease.
What makes this work distinctive is how deliberately interdisciplinary it is. PIONEER brings together leaders in nanomaterials and drug delivery; automation, AI and machine learning for chemistry; synthetic cell engineering; single-molecule biophysics; advanced spectroscopy; genome engineering; and single-cell genetics. The whole programme is built so these fields feed into one another rather than working in isolation. You would be joining a large collaborative team of PDRAs and PhD students whose culture is designed to enable early-career researchers to achieve ground-breaking results by working fluidly between disciplines. It is a rare opportunity to work at the intersection of several cutting-edge fields on a problem that will not only bring exciting new fundamental insights but also, if solved, would be a breakthrough for science and humanity.
The Opportunity: This is a rare chance to apply organic chemistry at the frontier of one of biology's great unsolved problems. You will design and synthesise novel small-molecule and ligand-based systems to ferry synthetic DNA across the double membrane of mitochondria, the energy-producing organelles that carry their own genome, enabling the first reliable platform for mitochondrial genome engineering and drug delivery and targeting.
The Science: For an organic chemist, this project offers something unusual: a molecule-to-organism design challenge where your ligand chemistry is the critical enabling step for the entire programme. You will be designing, synthesising, and iterating on mitochondria-targeting ligands, drawing on structure-activity relationships, physicochemical property optimisation, and an understanding of membrane partitioning, to create vehicles capable of transporting nucleic acid cargo into one of the cell's most chemically demanding environments. If you have ever wanted to apply medicinal chemistry thinking to a problem that goes beyond a single drug target, to something that could reshape how we treat a whole class of genetic disease, we highly recommend you apply.
The Team: You will be supervised by Dr. Nazila Kamaly and co-supervised by Dr. Becky Greenaway and Professor Kim Jelf’s labs who are establishing high throughput, AI and ML approaches as part of the project as well. Furthermore, you will be embedded in a large, genuinely interdisciplinary consortium of PDRAs and PhD students working across nanomaterials, automation, single-molecule biophysics, advanced spectroscopy, genome engineering, and single-cell genetics. The programme is explicitly designed so these fields feed into one another. you will have real opportunities to develop skills well beyond synthetic chemistry, including in high-throughput screening, machine learning-guided design, and biological validation.
Who We're Looking For: We are seeking candidates holding, or about to hold, a Master’s degree in chemistry or a closely related field. A strong background in organic and/or medicinal chemistry is particularly desirable, as is experience in or enthusiasm for high-throughput or automated techniques.
How to Apply: Interested applicants are warmly encouraged to get in touch by email with a CV and a brief statement describing their interest in the field and any relevant research experience. Please contact Dr. Nazila Kamaly: nazila.kamaly@imperial.ac.uk.
Funding Notes
Full funding is available for UK Home students only. Applicants should clearly state their eligibility for Home fee status (e.g. through UK citizenship or Settled Status) in their application. Further information on fee status can be found at: imperial.ac.uk/study/fees-and-funding/tuition-fees/fee-status/
About the Project
PIONEER (Programmable In-Organelle Nucleic-acid Entry, Expression and Retention) is an ambitious UK research consortium from Imperial College London, the University of Bristol, and the University of Glasgow, funded through the UK’s Advanced Research and Innovation Agency’s (ARIA) Precision Mitochondria programme, with a single bold goal: to build, from end to end, the ability to engineer the genome of mitochondria, the energy-producing compartments inside our cells. Mitochondria carry their own small genome, and reliably installing new, synthetic genetic material inside them has long been one of the great unsolved problems in biology. PIONEER sets out to crack it: to deliver large pieces of synthetic mitochondrial DNA across the mitochondria's notoriously difficult double membrane, switch on new genes inside, and make those changes stable over time. Ultimately, PIONEER seeks to demonstrate successful mitochondrial genome engineering in vivo and thereby open a new frontier for fundamental biology and for future therapies against mitochondrial disease.
What makes this work distinctive is how deliberately interdisciplinary it is. PIONEER brings together leaders in nanomaterials and drug delivery; automation, AI and machine learning for chemistry; synthetic cell engineering; single-molecule biophysics; advanced spectroscopy; genome engineering; and single-cell genetics. The whole programme is built so these fields feed into one another rather than working in isolation. You would be joining a large collaborative team of PDRAs and PhD students whose culture is designed to enable early-career researchers to achieve ground-breaking results by working fluidly between disciplines. It is a rare opportunity to work at the intersection of several cutting-edge fields on a problem that will not only bring exciting new fundamental insights but also, if solved, would be a breakthrough for science and humanity.
The Opportunity: This is a rare opportunity to place biological assay development and high-throughput screening at the heart of one of biology's great unsolved problems. As part of project PIONEER, the successful candidate will design and deploy cellular and biochemical assay pipelines to evaluate novel delivery systems targeting the mitochondria, the energy-producing organelles that carry their own genome, enabling the first reliable platform for mitochondrial genome engineering and targeted drug delivery.
The Science: This project offers something genuinely unusual: a role as the critical link between molecular design and biological reality. Novel mitochondria-targeting delivery vehicles will be synthesised by collaborators within the consortium, but it is the biological screening data generated in this PhD that will determine whether they work, and why. The successful candidate will develop and optimise high-throughput screening platforms to assess mitochondrial uptake, membrane integrity, cargo delivery efficiency, and cellular toxicity, working across live-cell imaging, flow cytometry, and functional genomic readouts. The screening data generated will directly drive the iterative design cycle of the entire programme, feeding into machine learning models that guide subsequent rounds of molecular design. Candidates who wish to build assay systems that actively accelerate discovery, rather than simply validate hypotheses, are strongly encouraged to apply.
The Team: The successful candidate will be supervised by Dr. Nazila Kamaly and embedded within a large, genuinely interdisciplinary consortium spanning nanomaterials, automation, single-molecule biophysics, advanced spectroscopy, genome engineering, and single-cell genetics. The role includes close collaboration with Professor Payam Gammage at the University of Glasgow, focusing on analysing the biooutputs of mitochondrial screening and applying those insights to the challenge of mitochondrial genome engineering. The project will also benefit from collaboration with Dr. Becky Greenaway and Professor Kim Jelfs, who lead the high-throughput automation, AI, and machine learning aspects of the programme.
The programme is explicitly designed so that biology, chemistry, and computation inform one another in real time. There will be genuine opportunities to develop skills across automated liquid handling, quantitative image analysis, machine learning guided experimental design, and mitochondrial cell biology, well beyond any single discipline.
Who We Are Looking For: Applications are sought from candidates holding, or about to hold, a Master's degree in biochemistry, cell biology, chemical biology, or a closely related field. A strong background in mammalian cell culture and quantitative biological assays is particularly desirable. Experience with high-throughput or automated screening platforms and live-cell imaging would be a significant advantage, as would enthusiasm for working at the interface of biology, chemistry, and data science. Prior experience in mitochondrial biology is welcome but not essential.
How to Apply: The project is supervised by Dr. Nazila Kamaly in the Department of Chemistry at Imperial College London and Professor Payam Gamage at University of Glasgow (email: payam.gammage@glasgow.ac.uk). Interested applicants are encouraged to apply or contact Dr. Nazila Kamaly directly, enclosing a CV and a brief statement describing their interest in the field and any relevant research experience (email: nazila.kamaly@imperial.ac.uk).
Funding Notes
Funding: Full funding is available for UK Home students only. Applicants should clearly state their eligibility for Home fee status (for example, through UK citizenship or Settled Status) in their application. Further information is available at: imperial.ac.uk/study/fees-and-funding/tuition-fees/fee-status/
PhD Studentship in Chemical Biology
Enzymatic Synthesis of Peptide Therapeutics
Imperial College, London
Applications are invited for a four-year PhD studentship funded by the European Research Council (ERC) project Enzymatic Methods for Peptide Synthesis (EZYPEP). The student will be based in the Department of Chemistry, Molecular Sciences Research Hub, Imperial College, under the supervision of Professor Jason Micklefield. Tuition fees will be covered and you will receive a tax-free stipend set at the UKRI-London rate (£22,780 2025-26) from September 2026.
Peptides are essential in life and are widely used as therapeutic agents, vaccines, biomaterials and in other important applications. Currently there are more than 80 peptide drugs approved world-wide, with many more in clinical trials, including essential antibiotics, antiviral and anticancer agents as well as treatments for diabetes. Most peptides are produced by solid phase peptide synthesis and related chemical methods that are outdated, problematic to scale-up, require large amounts of deleterious reagents and solvents that are damaging to the environment. In this PhD project we will address this problem by developing novel enzymatic methods for more sustainable, cleaner and scalable peptide assembly. The project will focus on developing next generation enzymatic peptide assembly technology that can deliver valuable pharmaceuticals ranging from small peptide drugs through to larger antibody drug conjugates (ADC). The PhD research programme will include: (i) using bioinformatics approaches to discover new ligases and other enzymes from nature, that facilitate peptide assembly and functionalisation; (ii) developing directed evolution approaches to improve the activity and substrate scope of the enzymes for peptide assembly; (iii) optimising processes for producing target peptides using novel separation methods to isolate peptide products.
Training will be provided in organic chemistry and biochemistry, including protein engineering, directed evolution, enzyme characterisation (X-ray crystallography and AI based modelling) and enzyme assays. Candidates are not expected to have expertise in all these areas at the outset; above all, scientific curiosity, and a desire to work in a multidisciplinary environment are most important. Candidates with a degree in Chemistry, Biochemistry, Biological Sciences or a related science, who also possess a desire to do cutting edge research at the Chemistry-Biology interface are encouraged to apply. Applicants should have, or expect to achieve, at least a 2.1 honours degree or a master’s in a relevant science related discipline. Applications including a brief cover letter, CV (no page limit), and the names of at least two referees should be sent by email to j.micklefield@imperial.ac.uk with the subject heading EZYPEP PhD.
Examples of related research and links from the Micklefield lab:
Cryptic enzymatic assembly of peptides armed with β-lactone warheads. Xu et al. Nature Chem Biol 2024, 20, 1371–1379. https://doi.org/10.1038/s41589-024-01657-7
Enzymatic synthesis of peptide therapeutics. Xu & Micklefield Nature Chem Biol 2024, 20, 1256–1257. https://doi.org/10.1038/s41589-024-01658-6
Discovery, Characterisation and Engineering of Ligases for Amide Synthesis. Winn et al Nature 2021, 593, 391–398. https://doi.org/10.1038/s41586-021-03447-w
Merging Enzymes with Chemocatalysis for Sustainable Amide Bond Synthesis. Bering et al Nature Commun. 2022, 13, 380. https://doi.org/10.1038/s41467-022-28005-4
Programmable late-stage C−H bond functionalization enabled by integration of enzymes with chemocatalysis. Craven et al. Nature Catalysis, 2021, 4, 385–394.
https://doi.org/10.1038/s41929-021-00603-3
https://www.micklefieldlab.chemistry.manchester.ac.uk
https://profiles.imperial.ac.uk/j.micklefield
Exploiting the Nuclear Recoil (Szilárd–Chalmers) Effect for the Separation of Neutron‑Irradiated Isotopes from Advanced Target Matrices
Supervisors: Dr Philip Miller (Imperial College London) and Dr Tom Haywood (Astral Systems)
Home Department: Departments of Chemistry at Imperial College London, Molecular Sciences Research Hub, White City Campus
Funding and Deadline: To be eligible for support, applicants must be UK Residents. The studentship is for 3.5 years starting as soon as possible and will provide full coverage of standard tuition fees and an annual tax-free stipend of approximately £21,240. Applicants should hold or expect to obtain a First-Class Honours or a high 2:1 degree at master's level (or equivalent) in any relevant chemical engineering or science subject. Funding is co-funded through the Department of Chemistry, Imperial College London and Astral Systems.
Project Summary
Neutron irradiation is an essential route to produce several high‑value radionuclides used in nuclear medicine and industry. Compact fusion-based neutron sources, such as those developed by Astral Systems, enable decentralised and flexible isotope production; however, efficient post‑irradiation separation remains a key technical bottleneck.
Particularly promising but under‑exploited phenomena in neutron‑activated targets is the nuclear recoil, or Szilárd-Chalmers effect, whereby threshold reactions or neutron capture impart sufficient energy to the product nucleus to break chemical bonds and displace it from its original lattice or coordination environment. When appropriately engineered, this effect can result in the radionuclide product being weakly bound, chemically labile, or spatially separated from the bulk target matrix.
This PhD project proposes to harness the Szilárd–Chalmers effect to facilitate isotopic separations. Using novel materials such as Metal‑Organic-Frameworks (MOFs) the candidate will investigate novel target matrices for neutron irradiation that will exploit for recoil‑driven displacement processes and to enable the selective release of isotopes following irradiation. An autonomous continuous process will be developed to rapidly separate and isolate recoil‑liberated radioisotopes from parent target material. The produced radioisotopes will have applications for medical imaging applications such as PET and SPECT imaging, and for radiotherapeutic applications.
We are seeking an ambitious and highly motivated candidate with a background in synthetic chemistry (organic or inorganic) who is willing to work with industry partners. No experience of working with radioactive material is required as full training will be provided.
To apply, please complete an application form Application process | Study | Imperial College London. Informal enquiries about the post and the application process can be made to Dr Philip Miller (philip.miller@imperial.ac.uk).
